Tapentadol Extended Release for Chronic Pain Patients
- 552 Downloads
Chronic pain reduces quality of life, utilizes healthcare resources, and increases healthcare costs. It is widespread, but generally inadequately treated or managed, partly due to several obstacles, including a limited number of mechanistic options for long-term pharmacologic agents. Opioids are generally the primary class of analgesic prescribed, but because of associated side effects during long-term treatment, many patients become noncompliant or discontinue treatment. A long-term use analgesic with a good benefit/risk ratio is advantageous.
A literature search for randomized trials using tapentadol extended release (ER) for noncancer chronic pain patients was conducted. Databases searched included PubMed, MEDLINE, EMBASE, and Google Scholar, using key terms “tapentadol,” “prolonged release,” “extended release,” and “chronic pain” individually or in combination. The results were synthesized and evaluated.
A total of six randomized, controlled studies were identified. Chronic pain conditions analyzed included low back, osteoarthritis, and diabetic peripheral neuropathy. Treatment arms consisted most often of placebo, tapentadol ER (100–250 mg twice daily [b.i.d.]), and/or oxycodone CR (controlled release) (20–50 mg b.i.d.). Subjects treated with tapentadol ER had significant reduction in pain intensity compared to placebo controls and similar efficacy to oxycodone CR. Overall, the safety profile was superior to that of oxycodone CR in regards to reduction in side effects, reduced severity of side effects (particularly gastrointestinal related), and lower study discontinuation rates.
The two mechanisms of analgesic action of tapentadol, combined with an ER, appears to provide equal efficacy to a strong controlled-release opioid while providing greater gastrointestinal tolerability. The reduction in incidence and severity of gastrointestinal side effects correlated with a higher compliance rate. These findings suggest that tapentadol ER might be a viable alternative to conventional strong opioids for pain management for chronic pain patients.
KeywordsAnalgesic Chronic pain Pain management Tapentadol extended release
Unable to display preview. Download preview PDF.
- 1.Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2012 ed. Washington, DC: National Academies Press; 2011.Google Scholar
- 6.David Michaelson & Company. Voices of Chronic Pain: A National Study. American Pain Foundation; 2006. Available at: http://www.davidmichaelsoncompany.com/Documents/Voices%20of%20Chronic%20Pain%20Report.pdf. Accessed Dec 14 2012.
- 11.Bennett MI, Closs SJ. Methodological issues in nonpharmacological trials for chronic pain. Anaesthesia, Pain & Intensive Care. 2010;14:49–55.Google Scholar
- 19.Henschke N, Ostelo RW, van Tulder MW, Vlaeyen JW, Morley S, Assendelft WJ, et al. Behavioural treatment for chronic low-back pain. Cochrane Database Syst Rev. 2010;(7):CD002014.Google Scholar
- 40.Tzschentke TM, Jahnel U, Kogel B, et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc). 2009;45:483–496.Google Scholar
- 41.Tzschentke TM, Christoph T, Kogel B, et al. (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265–276.PubMedCrossRefGoogle Scholar
- 44.NUCYNTAER (tapentadol extended release tablets) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; 2012. Available at: www.nucynta.com. Accessed Dec 14 2012.
- 45.Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and activecontrolled phase III study. Clin Drug Investig. 2010;30:489–505.PubMedCrossRefGoogle Scholar
- 46.Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11:1787–1804.PubMedCrossRefGoogle Scholar
- 49.Steigerwald I, Muller M, Kujawa J, et al. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release ondemand for the management of severe, chronic osteoarthritis-related knee pain: results of an openlabel, phase 3b study. J Pain Res. 2012;5:121–138.PubMedCrossRefGoogle Scholar
- 54.NUCYNTAER (tapentadol extended release tablets) [Risk Evaluation and Mitigation Strategy]. Titusville, NJ: Janssen Pharmaceuticals; 2011.Google Scholar
- 55.Food and Drug Administration. FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. Available at www.fda.gov. Accessed 14 Dec 2012.